Scientific publications
At Day One, we use the power of leading-edge science to improve patient outcomes.
We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
Nov 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial [published online ahead of print November 17, 2023]. Nat Med. 2023.
Nov 2023
Preliminary clinical activity of the type II RAF inhibitor tovorafenib in RAF-fusion-driven recurrent/progressive sarcomas.
Abstract 1552798. Preliminary clinical activity of the type II RAF inhibitor tovorafenib in RAF-fusion-driven recurrent/progressive sarcomas. Poster presentation at: The CTOS (Connective Tissue Oncology Society) 2023 Annual Meeting; November 1-4, 2023; Dublin, Ireland
June 2023
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFL Y-1 (PNOC026) study
2023 ASCO Annual Meeting, June 2-6, 2023, Chicago, IL & Online. Abstract number 10004
June 2023